Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin.
González Fernández S, Amador García Y, Boris Porras LG, Mojena Martínez L, Soler Porro LL, Pish Martí G, Fonseca Chon L, Estrada Guerra Y, Álvarez Blanco JM, Garabito Perdomo A, Santel Odio FB, Varona Vázquez LA, Ricardo Serrano YM, Chao González L, Avila Albuerne Y, Sánchez Valdés L, Viada González CE, Ramos Suzarte M, Saumell Nápoles Y. González Fernández S, et al. Among authors: viada gonzalez ce. J Oncol. 2022 Sep 1;2022:4128946. doi: 10.1155/2022/4128946. eCollection 2022. J Oncol. 2022. PMID: 36090901 Free PMC article.
Safety and effectiveness of CIMAvax-EGF administered in community polyclinics.
Ortiz Carrodeguas RA, Lorenzo Monteagudo G, Guerra Chaviano PP, Álvarez Montané I, Salomón Saldívar EE, Lobaina Lambert L, Camacho Sosa K, Bermúdez Pino R, Blanco Mustelier P, Valdés Rodríguez E, González Piloto S, Guerra de la Vega A, Valdés Sánchez L, Montes De Santis A, Parra Zabala J, Viada González C, Calvo Aguilera N, Saavedra Hernández D, Santos Morales O, Crombet Ramos T. Ortiz Carrodeguas RA, et al. Front Oncol. 2024 Jan 18;13:1287902. doi: 10.3389/fonc.2023.1287902. eCollection 2023. Front Oncol. 2024. PMID: 38304035 Free PMC article.
Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
Fernández Lorente A, Acosta Brooks S, Neninger Vinageras E, Barroso Alvarez Mdel C, Wilkinson Brito B, Troche Concepción M, Martínez Pérez LB, Viada González CE, Crespo Diaz T, Casacó Parada AR. Fernández Lorente A, et al. Among authors: viada gonzalez ce. World J Surg Oncol. 2013 Oct 15;11:275. doi: 10.1186/1477-7819-11-275. World J Surg Oncol. 2013. PMID: 24127898 Free PMC article.
Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study.
Santos-Morales O, Díaz-Machado A, Jiménez-Rodríguez D, Pomares-Iturralde Y, Festary-Casanovas T, González-Delgado CA, Pérez-Rodríguez S, Alfonso-Muñoz E, Viada-González C, Piedra-Sierra P, García-García I, Amaro-González D; NeuroEPO Study Group; García-Rodríguez JC, Sosa-Testé I, Lagarto-Parra A, Barrero-Viera L, David-Baldo M, Tamayo-Rodríguez M, Rivero-Vázquez I, González-Gamiz G, Martín-Trujillo A, Rodríguez-Fernández Y, Ledo-de la Luz AA, Álvarez-Delgado M, Howland-Álvarez I, Cruz-Gómez Y. Santos-Morales O, et al. BMC Neurol. 2017 Jul 4;17(1):129. doi: 10.1186/s12883-017-0908-0. BMC Neurol. 2017. PMID: 28676085 Free PMC article. Clinical Trial.
Erythropoietin in Spinocerebellar Ataxia Type 2: Feasibility and Proof-of-Principle Issues from a Randomized Controlled Study.
Rodriguez-Labrada R, Ortega-Sanchez R, Hernández Casaña P, Santos Morales O, Padrón-Estupiñan MDC, Batista-Nuñez M, Jiménez Rodríguez D, Canales-Ochoa N, Peña Acosta A, Medrano Montero J, Labrada Aguilera PE, Estupiñán Rodriguez A, Vazquez-Mojena Y, Almaguer Gotay D, Aymed-García J, García-García I, Torres Vega R, Viada González C, Valenzuela Silva CM, Silva Ricardo Y, Columbié Ximelis J, Tribin Rivero K, Valle Cabrera R, García-Rodriguez JC, Crombet Ramos T, Amaro-González D, Rodriguez-Obaya T, Velázquez-Pérez L. Rodriguez-Labrada R, et al. Mov Disord. 2022 Jul;37(7):1516-1525. doi: 10.1002/mds.29045. Epub 2022 May 23. Mov Disord. 2022. PMID: 35607776 Clinical Trial.
Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report).
Nodarse-Cuní H, Iznaga-Marín N, Viera-Alvarez D, Rodríguez-Gómez H, Fernández-Fernández H, Blanco-López Y, Viada-González C, López-Saura P; Cuban Group for the Study of Interferon in Recurrent Respiratory Papillomatosis. Nodarse-Cuní H, et al. J Laryngol Otol. 2004 Sep;118(9):681-7. doi: 10.1258/0022215042244741. J Laryngol Otol. 2004. PMID: 15517700 Clinical Trial.